Global Ursodeoxycholic
Acid Market, by Dosage Form (Solid Dosage Form and Liquid Dosage Form), by
Mode of Extraction (Synthetic and Biological), by Application (Gallstones,
Cystic Fibrosis, Liver Cirrhosis, and Others), and by Region (North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at
US$ 457.3 million in 2017 and is projected to exhibit a CAGR of 10.1% over the
forecast period (2018 – 2026).
Development of liquid
ursodeoxycholic acid can offer growth opportunities to market players, since
UDCA is currently prescribed only in solid form. Introducing a liquid
formulation of ursodeoxycholic acid would provide healthcare professionals an
alternate dosing method for patients who have difficulty swallowing tablets or
capsules. Major players in the market are focusing on receiving patents for
liquid formulation of UDCA. For instance, in June 2016, Retrophin, Inc. signed
a definitive agreement to purchase rights, titles, and ownership of a liquid
formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC.
Furthermore, in 2017, Retrophin announced plans to file a new drug application
(NDA) with the U.S. Food and Drug Administration for the liquid formulation of
ursodeoxycholic acid, to be used for treating primary biliary cholangitis
(PBC).
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2199
Browse 32 Market Data Tables and
22 Figures spread through 160 Pages and in-depth TOC on ‘Ursodeoxycholic Acid
Market’- Global Forecast to 2026, by Dosage Form (Solid Dosage Form and Liquid
Dosage Form), by Mode of Extraction (Synthetic and Biological), by Application
(Gallstones, Cystic Fibrosis, Liver Cirrhosis and Others) and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
The Asia Pacific region is
expected to be dominant in the ursodeoxycholic acid market over the forecast period,
due to reasons such as high prevalence of diseases such as gallstones and liver
cirrhosis. For instance, according to the data published by the OMICS
International, in India, liver cirrhosis resulted in 1.2 million deaths in
2013, increasing from 0.8 million deaths in 1990. Furthermore, key players in
the region are focusing on gaining approval for development of ursodeoxycholic
acid for novel indication. For instance, In February, 2019, EA Pharma is
developing nor-ursodeoxycholic acid for treatment of primary sclerosing
cholangitis (PSC), and non-alcoholic steatohepatitis (NASH) in Japan.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/ursodeoxycholic-acid-market-2199
Key Takeaways of the
Ursodeoxycholic Acid Market:
The global ursodeoxycholic acid
market is expected to exhibit a CAGR of 10.1% over the forecast period, owing
to rapid research in development of novel ursodeoxycholic acid. High prevalence
of diseases such as gallstone and liver cirrhosis is expected to fuel growth of
the market.
Among dosage form, solid dosage
form segment held dominant position in the ursodeoxycholic acid market in 2018,
owing to development of capsule and tablet form of Ursodeoxycholic acid (UDCA)
by various manufacturers such as Grindex and Intercept Pharmaceuticals, for
treatment of primary biliary cholangitis.
Among application, gall stones
segment held dominant position in the ursodeoxycholic acid market in 2018,
owing to increasing incidence of the condition. For instance, according to the
American Gastroenterological Association 2017 report, gallstones is affecting
10-15% of the U.S. population annually, which accounts for around 25 million
people.
Companies operating in the global
ursodeoxycholic acid market include Dipharma Francis Srl, ERREGIERRE S.p.A.,
Grindeks, Industria Chimica Emiliana, Mitsubishi Tanabe Pharma Corporation,
Zhongshan Belling Biotechnology Co., Glenmark Pharmaceutical Limited, Abil
Chempharma Private Limited, Biotavia Labs Pvt Ltd, Daewoong Bio Inc., PharmaZell
GmbH, and Suzhou Tianlu Bio-pharmaceutical Co., Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2199
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment